Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
870 participants
INTERVENTIONAL
2015-07-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa
NCT02028676
INTEGrating Ag-RDTs for COVID-19 in MNCH,HIV and TB Services in Cameroon and Kenya
NCT05382130
Strategic Antiretroviral Therapy and HIV Testing for Youth in Rural Africa
NCT03848728
Evaluation of the Integration of Ag-RDTs for COVID-19 in MNCH, HIV and TB Services in Cameroon and Kenya
NCT05498727
Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
NCT00557245
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods:
Design: The investigator will conduct in 3 health facilities a non-randomized controlled pragmatic trial comparing the effectiveness of the targeted (intervention arm) against the blanket PITC (control arm) in case finding and linkage of HIV-infected children and adolescents in HIV treatment.
Study population: For the intervention arm, the study population will be children and adolescents between 6 weeks to 19 years born to HIV-infected parents and the control arm will be children of the same age group seeking care in the hospital irrespective of the motive of consultations.
Procedure: The study will be implemented in the Limbe Regional Hospital (South West Region), the Abong-Mbang District Hospital (East Region) and the Ndop District Hospital (North West Region) in Cameroon for a period of 36 months. Prior to the conduct of the study, health facility staff will be trained in PITC implementation. Testing kits and supplies will be made available to the site. Enrolment in the 2 arms will be done simultaneously till completion of the sample size. The HIV testing and ART eligibility assessment will be done following the national guidelines.
Sample size calculation: Based on the results of the pilot of this targeted PITC, we believe that with its implementation, the yield of newly diagnosed HIV cases amongst children should at least equal the double of the yield the blanket PITC (control arm) in same health facility. Therefore, the investigators have calculated the sample size to detect the minimum effect in the intervention group equal to at least the double of the yield in the control arm. Computing the formula for sample size calculation of 2 independent samples, we obtained a sample size of 435 children per arm. Hence a total sample size of 870 children.
Data collection, management and analysis: Socio-demographic data for children and parents, HIV status and ART eligibility, linkage to care and HIV treatment outcome will be collected using standardized pre-tested questionnaires. A database will be developed on Microsoft Access for data entry. Data entry will be done progressively till the study sample size is attained. Data analysis will be done using SPSS software and findings will be reported using both descriptive and analytical statistics.
Ethical considerations: Parents' informed consent and children' assent will be required for enrollment into the study. The study will obtain an ethical clearance prior to implementation.
Outcome: This study will assess the effectiveness of targeted PITC in case identification and linkage of HIV-infected children to care/treatment. This new knowledge could be used to reduce the current global gap in pediatric and adolescent HIV treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention arm
The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
targeted Provider-Initiated-Testing and Counseling (tPITC)
The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
Control arm
The control arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years; consulting in the hospital for any motive. These children will be recruited for HIV testing at the outpatient department (OPD) and this through their accompany parents/guardians. Care providers will be advised to propose HIV testing systematically to all children and adolescents showing up at the OPD irrespective of the chief complaint.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
targeted Provider-Initiated-Testing and Counseling (tPITC)
The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Parents/guardians seeking care for their children in the hospital: Parents/guardians presenting at the hospital with sick children will be enrolled in the study irrespective of the motive of consultations for their children.
* Children of HIV infected parents: children of HIV infected parents aged between 6 weeks to 19 years old will be eligible for enrollment in the study. Parents/guardians consent will be required as well as assent of older kids.
* Children consulting in the hospital: Children aged 6 weeks to 19 years old consulting in the hospital for any reason will be eligible to participate in the study. Parents/guardians consent will be required as well as assent of older kids.
* HIV infected children: children (6weeks\<years\<19 years old) enrolled in HIV care in the hospital at least 2 years before the beginning of the project and after this beginning will be enrolled into the study to assess retention into care and factors associated with loss to follow up.
* Health personnel: Health personnel involved in children's consultations and consenting to participate will be enrolled in the study.
Exclusion Criteria
* HIV Status: Children with known HIV positive status will be excluded for HIV testing
* Age: Children below the age of 6 weeks or above 19 years will be excluded from the study
* Health conditions: parents who are critically ill or mentally unstable will be excluded from the study
6 Weeks
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Else Kröner Fresenius Foundation
OTHER
Albert Einstein College of Medicine
OTHER
Research for Development International
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Yumo, Habakkuk Azinyui
Dr Yumo, Habakkuk Azinyui, MD, MPH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Habakkuk Yumo, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Research for Development International
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Abong-Mbang District Hospital
Abong Mbang, East Region, Cameroon
Ndop District Hospital
Ndop, North-West Region, Cameroon
Limbe Regional Hospital
Limbe, , Cameroon
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yumo HA, Ajeh RA, Sieleunou I, Ndenkeh JN Jr, Jordan MR, Sam-Agudu NA, Kuaban C, Loescher T. Parental and child-level predictors of HIV testing uptake, seropositivity and treatment initiation among children and adolescents in Cameroon. PLoS One. 2020 Apr 13;15(4):e0230988. doi: 10.1371/journal.pone.0230988. eCollection 2020.
Yumo HA, Kuaban C, Ajeh RA, Nji AM, Nash D, Kathryn A, Beissner M, Loescher T. Active case finding: comparison of the acceptability, feasibility and effectiveness of targeted versus blanket provider-initiated-testing and counseling of HIV among children and adolescents in Cameroon. BMC Pediatr. 2018 Sep 25;18(1):309. doi: 10.1186/s12887-018-1276-7.
Related Links
Access external resources that provide additional context or updates about the study.
Research for Development International
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R4D0007/2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.